Vaccine Therapy in Treating Patients Receiving Trastuzumab For HER2-Positive Stage IIIB-IV Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: HER2-positive Breast Cancer|Male Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer
Interventions: BIOLOGICAL: HER-2/neu intracellular domain protein|PROCEDURE: leukapheresis|OTHER: laboratory biomarker analysis|BIOLOGICAL: sargramostim|OTHER: immunologic technique|BIOLOGICAL: synthetic tumor-associated peptide vaccine therapy
Sponsor: University of Washington
Collaborators: National Cancer Institute (NCI)